Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Centipeda minima + PD-1/PD-L1 inhibitors in lung cancer
NCT05735028Phase 1Recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Feb 2024
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of centipeda minima in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoints: Progression-free survival at 2 years, Body temperature at 2 years and 3 more. Started Feb 2024; status: recruiting.
02
Drugs
centipeda minima
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05735028.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05735028.